<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014010516079N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-04-26</date_registration>
      <primary_sponsor>Vice chancellor for research, Isfahan University of Medical Sciences</primary_sponsor>
      <public_title>Dapsone gel in the treatment of papulopustular rosacea</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of dapsone 5% Topical gel with metronidazole 0.75% efficacy in combination with oral doxycycline In papulopustular rosacea</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-04-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/15143</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Double blinding in this study was done in a manner that both patients and researchers were not aware that which kind of exposure was done. In fact Metronidazloe and dapsone topical preparations  had the same appearance and only by a code placed in an envelope it could be determined whether the agent is actual drug or placebo.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Papulopustular Rosacea.</hc_freetext>
      <i_freetext>Intervention 1: Topical 5% dapsone gel were administered for group D and applied on the face twice daily for 12 weeks with systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day. Mode of use and application in the study: apply twice a day, every day, for 12 weeks .The cases are advised to wash the entire affected area with a mild cleanser and pat dry with a clean towel then apply a thin layer of the gel onto the entire affected area (a pea-sized amount will usually be enough), then gently and completely rub the gel right into their skin.In order to supply the dapsone gel , dapsone powder was dissolved in ethanol and then prepared in gel vehicle up to 5% concentration.Powder of dapsone , odorless crystalline powder, is applied in an aqueous gel base for topical dermatologic use. Base or vehicle of the gel is composed of: Diethylene Glycol Monoethyl Ether; Methylparaben; Sodium Hydroxide; and purified water.treatment and total follow up period was 12 weeks. Intervention 2: Topical 0.75% metronidazole gel were administered for group  M and applied on the face twice daily for12 weeks with Systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day.Mode of Use and application in the study: apply twice a day, every day, for 12 weeks .The cases are advised to wash the entire affected area with a mild cleanser and pat dry with a clean towel then Apply a thin layer of the gel onto the entire affected area (a pea-sized amount will usually be enough), then gently and completely rub the gel right into their skin.Topical Metronidazole gel was prepared  similar in shape, odor, size and color to dapsone gel, and applied in an aqueous gel base for topical dermatologic use. Base or vehicle of the gel is composed of: Diethylene Glycol Monoethyl Ether; Methylparaben; Sodium Hydroxide; and purified water.treatment and total follow up period was 12 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Parastoo Khosravani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology group, Al-zahra hospital, Soffeh Blvd, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 1625 5555</telephone>
        <email>p_khosravani@resident.mui.ac.ir</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Gita Faghihi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology group, Al-zahra hospital, Soffeh Blvd, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 1625 5555</telephone>
        <email>G_faghihi@med.mui.ac.ir</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: age between 18 and 55,  patients with papulopustular facial  rosacea, negative history of using topical steroid or retinoic acid during last month, negative history of using oral anti-inflammatory agents and oral retinoic acids  during last  month and last 180 days respectively &#13;
Exclusion criteria:  Pregnancy or lactation, any history of G6PD deficiency, any history of hypersensitivity to dapsone or metronidazole, any history of oral cotrimoxasole treatment</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L71.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other rosacea</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Topical 5% dapsone gel were administered for group D and applied on the face twice daily for 12 weeks with systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day. Mode of use and application in the study: apply twice a day, every day, for 12 weeks .The cases are advised to wash the entire affected area with a mild cleanser and pat dry with a clean towel then apply a thin layer of the gel onto the entire affected area (a pea-sized amount will usually be enough), then gently and completely rub the gel right into their skin.In order to supply the dapsone gel , dapsone powder was dissolved in ethanol and then prepared in gel vehicle up to 5% concentration.Powder of dapsone , odorless crystalline powder, is applied in an aqueous gel base for topical dermatologic use. Base or vehicle of the gel is composed of: Diethylene Glycol Monoethyl Ether; Methylparaben; Sodium Hydroxide; and purified water.treatment and total follow up period was 12 weeks.</i_keyword>
      <i_keyword>Topical 0.75% metronidazole gel were administered for group  M and applied on the face twice daily for12 weeks with Systemic doxycycline capsule (Sobhan Darou Co.), 100 mg/day.Mode of Use and application in the study: apply twice a day, every day, for 12 weeks .The cases are advised to wash the entire affected area with a mild cleanser and pat dry with a clean towel then Apply a thin layer of the gel onto the entire affected area (a pea-sized amount will usually be enough), then gently and completely rub the gel right into their skin.Topical Metronidazole gel was prepared  similar in shape, odor, size and color to dapsone gel, and applied in an aqueous gel base for topical dermatologic use. Base or vehicle of the gel is composed of: Diethylene Glycol Monoethyl Ether; Methylparaben; Sodium Hydroxide; and purified water.treatment and total follow up period was 12 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Rasoacea papulopustular lesions. Timepoint: Baseline, week 4, week 8, week 12. Method of measurement: Number of inflammatory lesions, Visual analogue score (VAS.) and  Investigator’s global assessment  scores (IGA.).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side effects of drug. Timepoint: Every 4 weeks. Method of measurement: clinical evaluation-laboratory test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-02-14</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar Jerib Aven, Isfahan Isfahan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
